Page 5 - Milestone Payment News Today

Share: Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China National Ethics Committee Approval for GPS Phase 3 REGAL Study Received in Greece Preparations Underway to Activate Clinical Trial Sites and Enroll Patients in the REGAL Study in France, Germany and Greece by End of Second Quarter 2021 NEW YORK, May 13, 2021 (GLOBE NEWSW...

TeneoBio, Inc Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...

Australis Completes Definitive Agreement to Acquire 51% Stake in ALPS News provided by Share this article ALPS Business Accelerating - Contracts Signed in Past 5 Weeks for Total North of $5 Million ALPS Core Element in AUSAs Unique Capital-Light Expansion Strategy Terry Booth to Take the Helm as CEO upon Closing LAS VEGAS, Feb. 24, 2021 /PRNewswire/ - Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company") announced today that, further to its press release dated January 5, 20...

Australis Enters Into Term Sheet to Acquire ALPS News provided by Share this article Back-end Loaded Terms Create Strong Alignment with Shareholders Interests Access to Low-Cost, High-Quality Biomass to Fuel Capital-Light Scale-up of Brands Terry Booth to Become CEO Company Will Host Conference Call Thursday, January 7, 2021 at 12:00 pm ET LAS VEGAS, Jan. 5, 2021 /PRNewswire/ - Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) ("AUSA" or the "Company") and 2750176 Ontario Inc. ("ALPS") today an...